Generally, there is a problem in using systemic administration of CCK2-receptor antagonist in the therapy of panic disorder and other neuropsychiatric disorders, because CCK peptides and CCK2-receptors are so abundantly expressed in almost all regions of the brain [27,28,29,100] and not only in limbic structures, such as the amygdala. Here, CCKBR is linked to panic disorder.